Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

27.10.2026

Aspen Manufacturing to Drive 2027 Growth After mRNA Loss

Aspen Manufacturing to more than double EBITDA in 2027 as sterile operations, insulin and new production lines replace a lost mRNA deal.
Aspen Manufacturing to Drive 2027 Growth After mRNA Loss
Image | Rushay | Shutterstock/2517348357

Aspen manufacturing is expected to drive the group's earnings growth in the 2027 financial year, as the company works to replace business lost when a major mRNA production contract ended. Aspen Pharmacare forecasts that manufacturing EBITDA will more than double this year, according to its 2026 integrated report.

In the year to end-June, factory EBITDA rose 21% to R828 million in constant currency terms. However, manufacturing revenue fell 10% to R9.5 billion.

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

More from Health Matters

27.10.2026

District Health Leadership: Tackling Fear in Frontline Care

Understand the significance of district health leadership in fostering trust and improving healthcare in South Africa's public facilities.

26.10.2026

Gauteng Health Dept Should Be Placed Under Administration

Critics say the Gauteng health department should be placed under administration as chronic medicine shortages force patients to split pills.

25.10.2026

Gap Cover Undermines Scheme Cost Controls

Actuaries warn that gap cover and primary healthcare plans are shifting costs and undermining medical scheme efforts to contain spending.